Lopinavir

Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that

Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that

Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that

Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that

Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

A potent inhibitor of HIV-1 protease (Ki = 1.3 pM) that blocks the replication of laboratory and clinical strains of HIV-1 (EC₅₀ = 6-17 nM) and is effective against certain mutant strains.

A potent inhibitor of HIV-1 protease (Ki = 1.3 pM) that blocks the replication of laboratory and clinical strains of HIV-1 (EC₅₀ = 6-17 nM) and is effective against certain mutant strains.

A potent inhibitor of HIV-1 protease (Ki = 1.3 pM) that blocks the replication of laboratory and clinical strains of HIV-1 (EC₅₀ = 6-17 nM) and is effective against certain mutant strains.

A potent inhibitor of HIV-1 protease (Ki = 1.3 pM) that blocks the replication of laboratory and clinical strains of HIV-1 (EC₅₀ = 6-17 nM) and is effective against certain mutant strains.